NASAL DRUG DELIVERY MODE MARKET ANALYSIS

Nasal Drug Delivery Mode Market, By Therapeutic Application (Asthma, Rhinitis, and Others), By Dosage Form (Powder, Gel. Spray, and Gel), By Container Type (Pressurized Container, Non Pressurized, and Container), By System Type (Multi- Dose, Bi-Dose, and Unit Dose), By End Users (Hospitals and Homecare Settings), By Distribution (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Recent Developments:

In June 2020, GlaxoSmithKline (GSK) added a natural saline nasal spray for the relief of hay fever and other allergy symptoms to its Piri range. The PiriNatural spray can help reduce nasal congestion caused by allergies by cleaning and washing nasal cavities with isotonic seawater and aloe vera, according to the company.
In March 2020, Evolve BioSystems, Inc. announced a collaboration with Janssen Research & Development to conduct a clinical study in children at risk for developing atopic dermatitis. It aims to investigate whether infant probiotic evivo can reduce development of early childhood atopic dermatitis, which is implicated in asthma, allergic rhinitis, and food allergies.

Market Trends/Key Takeaways:

Outbreak of COVID-19 (pandemic) is expected to propel the growth of the global nasal drug delivery mode market. For instance, in August 2021, Glenmark Pharmaceuticals and SaNOtize Research & Development Corp. teamed up to manufacture, market, and distribute its Nitric Oxide Nasal Spray (NONS) for the treatment of COVID-19 in India and other Asian markets including Hong Kong, Malaysia, Singapore, and other countries.
Introduction of novel products and/or frequent approvals and launches of novel products are expected to aid in the growth of the global nasal drug delivery mode market. For instance, in March 2019, Aptar Pharma announced that its Bidose nasal spray device was recently approved by the U.S. FDA for a breakthrough therapy in the field of depression.